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Abstract 
 
Inflammation is implicated in the etiology of Major Depressive Disorder (MDD). Human 
neuroimaging techniques are increasingly used to characterize the neural circuitry 
mediating actions of inflammation on mood, motivation and cognition and its relationship 
to MDD. In this issue, Byrne and colleagues report the first systematic review of these 
studies. The systematic review provides a much-needed synthesis of current research 
findings and highlights the role of cortical and subcortical brain structure and function. In 
this accompanying commentary, we highlight further points of particular relevance to future 
studies, including the potential advantages of functional phenotype models rather than the 
emphasis on mutually exclusive diagnostic categories in describing MDD and other 
psychiatric disorders. Novel imaging techniques will further enhance possibilities to clarify 
the link between inflammation and depression. New research challenges are described 
regarding the relationships between behavioural phenotype, brain structure and function, 
and peripheral inflammation.  
  
Major Depressive Disorder (MDD) is one of the leading causes of disability worldwide and 
significantly worsens prognosis and quality of life for people with comorbid physical 
disorders. Yet despite this major global burden, advances in understanding MDD 
pathogenesis have been slow, and translational breakthroughs disappointingly rare. Over 
the past two decades a surge of research has focused on understanding the role of 
inflammation in major mental illnesses. In MDD, characteristic alterations in serum 
cytokines, chemokines and acute phase reactant protein concentrations have been 
confirmed in at least 4 recent meta-analyses (1-4). Furthermore, longitudinal studies 
suggest that inflammatory changes predate and likely contribute to the development of 
depressive symptoms (5); findings that accord with the observation that 1 in 4 patients 
treated with Interferon-alpha (for hepatitis-C) develop MDD. These studies challenge the 
long held view of the brain as an ͂immune privileged site̓. By characterizing the bi-
directional interactions between physiological stress responses, immune/inflammatory 
pathways and the brain, they are also beginning to offer a coherent neurobiological 
framework for understanding this multi-componential disorder (6, 7). This framework 
additionally offers the prospect of identifying circulating inflammatory biomarkers for 
treatment response, and novel anti-inflammatory agents as adjunctive therapies for 
treatment resistance (8, 9). 
While preclinical studies have helped clarify actions of systemic inflammation on regional 
brain structure and function, the use of advanced brain imaging techniques to explore 
similar relationships in clinical studies remains in a fledgling state.  
In the current issue of Psychosomatic Medicine, Byrne and colleagues report the first 
systematic review of studies using brain imaging to characterize the neural mechanisms 
linking inflammation and depressive symptoms (10). They reviewed 26 studies that report 
effects of both experimentally induced inflammation and inflammation in the context of 
MDD and identify a cluster of subcortical (basal ganglia, ventral striatum, hippocampus, 
hypothalamus and amygdala) and cortical (insula, anterior cingulate, orbitofrontal, 
ventromedial, and dorsolateral prefrontal cortices) structures that appear central to effects 
of inflammation on mood and depressive symptomatology. This review provides a much-
needed synthesis of current research findings, highlights caveats of the existing literature 
and points towards potential pathways for future research. In this editorial, we highlight 
issues that will need to be addressed in future studies exploring relationships between 
behavioural phenotype, brain and peripheral inflammation, and examine how refining these 
measurements will be crucial to further progress. 
 
Measuring the right phenotype:  
While most studies find a relationship between inflammation and MDD, it is important to 
note that a significant proportion of people with MDD do not show raised inflammatory 
markers. Furthermore, immune/inflammatory disruption is also found in a number of other 
psychiatric conditions, including schizophrenia and PTSD (11, 12). Inflammation is therefore 
neither necessary nor specific to MDD. Complicating this further, we know that depressive 
symptoms are not limited to MDD, but instead are common in patients diagnosed with a 
range of other illnesses including anxiety disorders and psychosis. This highlights the highly 
heterogeneous nature of current psychiatric diagnostic categories (13) which frequently 
share overlapping symptomatology, genetic and biological susceptibility (14) and likely 
mitigates success of attempts to map diagnoses to specific alterations in brain 
structure/function. This problem is widely acknowledged across psychiatric research and 
has led to the recognition that a categorical (diagnostic criteria based) approach may be 
impeding biologically relevant translational research (15). In keeping with this, there is a 
move to replace existing categorical models of mental illnesses, with trans-diagnostic 
dimensional models that incorporate genes, biology and cognitive neuroscience (16). There 
is also a move towards implementing computational models of psychiatric symptomatology 
that may better map complex cognitive and behavioural constructs at the neuronal level 
(17). Therefore, rather than exploring associations within specific illness categories, future 
research may need to look at associations between inflammation and research domains or 
computational models of complex cognitive/ behavioural functions. 
Measuring the brain: 
Neuroimaging is a fast evolving field. While traditional neuroimaging approaches have 
examined how measured variables (cognitive function/ inflammatory markers) are 
correlated with patterns of activation, volume or metabolism on a region-by-region basis, 
more recent studies have focused on "how" these processes are implemented and 
distributed across brain regions using advanced computational modelling. The latter 
approaches are enabling us to better understand how networks of regions interact together 
to support complex behaviors. 
By regressing variables derived from competing computational models of a specific 
cognitive function, model-based approaches to fMRI provide insight into ͂how̓ rather 
than simply ͂where̓ a particular cognitive process is implemented within the brain. This 
approach also has the potential to provide a more fine-grained understanding of brain 
responses to inflammation. For example, in their review, Byrne et al. identify the ventral 
striatum and insula as key brain regions sensitive to systemic inflammation. Using a 
reinforcement-learning model, Harrison et al. deconstruct the concept of 'motivational 
reorientation', a core feature of inflammation induced sickness-behavior, to show that 
experimentally induced inflammation significantly enhances sensitivity to punishments 
versus rewards (18). Furthermore, they showed that prediction error (PE) signals (difference 
between expected and obtained reward/punishment) believed to guide learning were 
significantly modulated by inflammation, with inflammation prompting a significant 
reduction in ventral striatal encoding of reward PE and a converse enhancement of insula 
encoding of punishment PE. Model-based studies such as this will be essential to future 
attempts to understand how inflammation alters specific neural computational mechanisms 
that lead to observed changes in behavior. 
A second approach gaining increasing importance is the use of resting state fMRI to explore 
how dynamically interacting core intrinsic connectivity networks (ICN), are altered by 
inflammatory stimuli. For example, Felger et al. recently showed an inverse association 
between circulating C-reactive protein (CRP) levels and striatal functional connectivity in 
MDD (19). Other key substrates identified by Byrne et al. include the anterior insula and 
anterior cingulate cortices. These regions are noteworthy as they both form key nodes of 
the salience network (SN) implicated in allocating attentional resources to behaviorally 
relevant external and internal stimuli (20-22). Furthermore, internal (interoceptive) signals 
from the body are postulated to have a primary 'viscero-cortical' representation within the 
SN. Inflammatory mediators, are known to activate vagal afferents and the sensory 
circumventricular organs as well as the brainstem ͂viscerosensory hub̓ evoking visceral 
reflexes and subjective experiences of fatigue, malaise, and anorexia (21, 23). Further 
upstream, involvement of the SN may also be associated with aberrant salience mapping 
(24). The centrality of the insula to autonomic, interoceptive, and viscero-cortical 
representation, together with its role in ͂switching̓ between brain states, make it an 
ideal candidate for investigating how interoceptive inflammatory signals modulate complex 
neurocognitive function.  
Resting state fMRI has also been used to explore effects of inflammation on global network 
function using graph theoretical metrics derived from complex network analysis (CNA). 
Using CNA of resting state BOLD cross-correlations Dipasquale et al. have recently shown 
that peripherally administered IFN-α rapidly reduces global network connectivity and 
network efficiency indicating a global reduction in information transfer among nodes 
forming the whole brain network (25). Similar data-driven approaches could include 
investigating how inflammation affects the regional homogeneity (ReHo) of BOLD signals, a 
measure shown to be disrupted in a regionally specific manner in MDD (26). In this regard, 
Byrne et al. found evidence to support effects of inflammation on glutamatergic activity 
(10). Measures such as the amplitude of low frequency fluctuations (alFF) may be a useful 
index to further quantify how these inflammation-induced changes in glutamatergic 
function relate to observed alterations in BOLD fluctuations at rest (27). Finally, newer MRI 
based sequences like quantitative magnetization transfer (qMT), neurite orientation 
dispersion and density imaging (NODDI) and free water imaging also appear to be promising 
approaches for characterizing effects of inflammation on brain pathophysiology (28-30). 
Future studies are likely to see increasing use of these complimentary imaging technologies 
to understand how inflammation-induced changes in brain microstructure relate to 
associated changes in function. 
Measuring inflammatory markers: 
Three points appear crucial when measuring inflammatory markers. Firstly, it is essential to 
dissect effects of 'non-sterile' inflammation (induced by infection/experimental 
cytokines/vaccines/endotoxins) from inflammation secondary to 'sterile' stressors e.g. 
psychological stress (31) and furthermore recognize that not all ͂non-sterile̓ challenges 
recruit the same signal transduction pathways (32). Although there is increasing evidence 
for "inflammasome" activation and aggregation in response to both sterile and non-sterile 
inflammation, these effects still need to be qualified and quantified (33, 34). Similarly, while 
experimental induction of inflammation may help quantify effects of inflammation in the 
absence of confounding factors, in real life this is rarely the case. For example, previous 
studies have illustrated how inflammatory markers may mediate the relationship between 
socioeconomic status and grey/ white matter structure (35-37). However, it remains unclear 
whether inflammatory pathways linking real-life sustained stressful conditions to the brain 
differ from those associated with experimentally induced inflammation. 
Secondly, it remains unclear to what extent  circulating inflammatory markers reflect central 
levels. While most of the studies reviewed by Byrne and colleagues examined associations 
between circulating inflammatory markers and brain structure/ function, few measured 
central inflammatory markers. In this regard it is interesting to note that Haroon et al., 
recently found a high correlation between plasma and cerebrospinal fluid (CSF) CRP, yet 
only plasma measures correlated with basal ganglia glutamate (38). Other studies have 
found no relationship between circulating and CSF inflammatory markers (39, 40).  
Measuring CSF/central inflammation is further complicated by the presence of both soluble 
and cell bound cytokines fractions in the brain. For example, microglial activity produces 
predominantly bound tumor necrosis factor (TNF) that is difficult to measure (39). 
Moreover, there has not been a consistent relationship between CSF inflammatory markers 
and MDD (40-42). Some studies have used 18nDa translocator protein (TSPO) Positron 
Emission Tomography (PET) which is expressed on activated microglia to quantify central 
inflammation. In an interesting recent study, Sandiego et al. showed that endotoxin 
challenge in healthy adults results in rapid and widespread microglial activation throughout 
the brain (43). However, findings using TSPO binding in MDD have been mixed (10). 
Furthermore, TSPO PET studies are not without their own difficulties. TSPO PET is expensive, 
existing TSPO ligands like [11C]PK11195 have poor signal to noise ratio and newer tracers like 
[11C]PBR28 show marked between subject variations in binding affinity (44). Additionally, 
not all microglia express TSPO, and TSPO PET cannot differentiate an increase in microglial 
number from an increase in TSPO expression within each microglia (44).  
 A third issue is identifying what markers of inflammation should we be measuring. 
Most research to date has focused on investigating relationships between pro-inflammatory 
cytokines and psychiatric illnesses. Similarly, most of the studies cited by Byrne et al. only 
measured cytokines identified by the meta-analyses linking inflammation to depression (4). 
Here, the underlying assumption is that excess pro-inflammatory cytokines are harmful to 
the brain. However, it is clear that some pro-inflammatory cytokines such as TNF are 
required for healthy CNS function (45). While a simple division between pro-and anti-
inflammatory cytokines may be artificial, a balance between different inflammatory markers 
clearly exists within the body. Furthermore, chemokines and colony-stimulating factors have 
also been linked to cognitive dysfunction and the pathophysiology of psychiatric symptom 
clusters (46). Given the complex interplay between these factors sophisticated modeling 
using techniques such as principal component analysis, hierarchical or other advanced 
clustering techniques are likely to be required to fully capture how changes in networks of 
interacting inflammatory markers act on the brain to induce associated changes in behavior 
and cognition (47).  
To conclude, raised inflammatory markers have been associated with a number of 
psychiatric conditions including depression and may indeed play an etiological role in these 
disorders. Inflammation may perhaps be better conceptualized as a generalized 
physiological (or pathological) response to a stressor (sterile or non-sterile) that triggers a 
cascade of events that affect core information processing systems in the brain, leading 
ultimately to a discrete behavioural phenotype (e.g. anhedonia / motivational reorientation) 
that spans diagnostic categories.  Although the key mechanisms linking inflammatory factors 
to the human brain are gradually being established, future work will need to focus on 
refining peripheral immune measures. These research findings, together with the 
application of advanced brain-imaging techniques, should help us to move closer to the goal 
of understanding more precisely the relationship between peripheral inflammation, regional 
brain structure / function and associated changes in discrete clinical and cognitive 
phenotypes. 
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